Literature DB >> 23234416

Upper airway dilator muscle weakness following intermittent and sustained hypoxia in the rat: effects of a superoxide scavenger.

J R Skelly1, S C Rowan, J F X Jones, K D O'Halloran.   

Abstract

Obstructive sleep apnoea syndrome (OSAS) is a common disorder associated with upper airway muscle dysfunction. Agents that improve respiratory muscle performance may have considerable therapeutic value. We examined the effects of acute exposure to sustained and intermittent hypoxia on rat pharyngeal dilator muscle function. Additionally, we sought to test the efficacy of antioxidant treatment in ameliorating or preventing hypoxia-related muscle dysfunction. Isometric contractile and endurance properties of isolated rat sternohyoid muscle bundles were examined at 35 °C in vitro. Muscle bundles were exposed to one of four gas treatments: hyperoxia (control), sustained hypoxia (SH), intermittent hypoxia (IH) or hypoxia/re-oxygenation (HR), in the absence or presence of the superoxide scavenger--Tempol (10 mM). Stress-frequency relationship was determined in response to electrical stimulation (10-100 Hz in increments of 10-20 Hz, train duration: 300 ms). Muscle performance was also assessed during repetitive muscle stimulation (40 Hz, 300 ms every 2 s for 2.5 min). Compared to control, IH and HR treatments significantly decreased sternohyoid muscle force. The negative inotropic effect of the two gas protocols was similar, but both were of lesser magnitude than the effects of SH. SH, but not IH and HR, increased muscle fatigue. Tempol significantly increased sensitivity to stimulation in all muscle preparations and caused a leftward shift in the stress-frequency relationship of IH and SH treated muscles. Tempol did not ameliorate sternohyoid muscle fatigue during SH. We conclude that Tempol increases upper airway muscle sensitivity to stimulation but only modestly ameliorates respiratory muscle weakness during intermittent and sustained hypoxic conditions in vitro. Respiratory muscle fatigue during sustained hypoxia appears unrelated to oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23234416     DOI: 10.33549/physiolres.932405

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  6 in total

Review 1.  The polymorphic and contradictory aspects of intermittent hypoxia.

Authors:  Isaac Almendros; Yang Wang; David Gozal
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-05-16       Impact factor: 5.464

Review 2.  Obstructive Sleep Apnea, Hypoxia, and Nonalcoholic Fatty Liver Disease.

Authors:  Omar A Mesarwi; Rohit Loomba; Atul Malhotra
Journal:  Am J Respir Crit Care Med       Date:  2019-04-01       Impact factor: 21.405

3.  Chronic sustained hypoxia-induced redox remodeling causes contractile dysfunction in mouse sternohyoid muscle.

Authors:  Philip Lewis; David Sheehan; Renata Soares; Ana Varela Coelho; Ken D O'Halloran
Journal:  Front Physiol       Date:  2015-04-20       Impact factor: 4.566

4.  Inflammatory lung disease in Rett syndrome.

Authors:  Claudio De Felice; Marcello Rossi; Silvia Leoncini; Glauco Chisci; Cinzia Signorini; Giuseppina Lonetti; Laura Vannuccini; Donatella Spina; Alessandro Ginori; Ingrid Iacona; Alessio Cortelazzo; Alessandra Pecorelli; Giuseppe Valacchi; Lucia Ciccoli; Tommaso Pizzorusso; Joussef Hayek
Journal:  Mediators Inflamm       Date:  2014-03-17       Impact factor: 4.711

5.  Chronic intermittent hypoxia increases rat sternohyoid muscle NADPH oxidase expression with attendant modest oxidative stress.

Authors:  Robert Williams; Paul Lemaire; Philip Lewis; Fiona B McDonald; Eric Lucking; Sean Hogan; David Sheehan; Vincent Healy; Ken D O'Halloran
Journal:  Front Physiol       Date:  2015-01-30       Impact factor: 4.566

6.  NADPH oxidase 2 is necessary for chronic intermittent hypoxia-induced sternohyoid muscle weakness in adult male mice.

Authors:  Sarah E Drummond; David P Burns; Sarah El Maghrani; Oscar Ziegler; Vincent Healy; Ken D O'Halloran
Journal:  Exp Physiol       Date:  2022-07-11       Impact factor: 2.858

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.